https://market.us/privacy-policy/https://market.us/privacy-policy/
Global Drug Delivery Devices Market size is expected to be worth around US$ 862.16 Billion by 2034 from US$ 410.61 Billion in 2024.
https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy
The Connected Drug Delivery Devices Market is estimated to be valued at USD 845.9 million in 2025 and is projected to reach USD 7039.1 million by 2035, registering a compound annual growth rate (CAGR) of 23.6% over the forecast period.
Metric | Value |
---|---|
Industry Size (2025E) | USD 845.9 million |
Industry Value (2035F) | USD 7039.1 million |
CAGR (2025 to 2035) | 23.6% |
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
Connected Drug Delivery Devices Market Report is Segmented by Product Type(Connected Sensors [Connected Inhaler Sensors and More] and Integrated Connected Devices [Connected Inhalers and More), Technology (Bluetooth, Near-Field Communication and More), End User (Healthcare Providers, Homecare and More), Application (Respiratory Diseases, Diabetes and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).
https://media.market.us/privacy-policyhttps://media.market.us/privacy-policy
Global Drug Delivery Devices Market size is expected to be worth around USD 713.1 Billion by 2033, from USD 333.4 Billion in 2023, growing at a CAGR of 7.9% during the forecast period from 2024 to 2033.
Drug delivery devices are specialized tools engineered to administer medications in a precise and controlled manner, directly enhancing drug efficacy, safety, and patient adherence. These devices range from external equipment like inhalers, injectors, and pumps, to internal mechanisms such as implants, and are utilized to deliver a broad spectrum of therapeutic agents, including small molecules, biologics, and vaccines. They optimize drug release rates, improve bioavailability, facilitate absorption, and can even provide real-time monitoring and feedback mechanisms for both patients and healthcare providers. This capability is crucial in managing various health conditions effectively, from chronic diseases to infectious ailments and cancer.
The integration of advanced technologies in these devices aims to refine drug delivery to targeted areas, thus minimizing dosage requirements and reducing potential side effects. This precision not only enhances therapeutic outcomes but also contributes to the cost-effectiveness of treatments by lowering the quantities of active pharmaceutical ingredients needed. The burgeoning demand for innovative drug delivery solutions is fueling research and development within the sector.
Currently, the market for drug delivery devices is expanding rapidly, propelled by increasing incidences of chronic and acute diseases, continuous advancements in biologic drug devices, and heightened awareness concerning diagnostic and therapeutic options. This growth is supported by a robust competitive landscape, where numerous companies offer an array of diagnostic tools designed to meet the varied requirements of healthcare systems globally.
https://www.polarismarketresearch.com/privacy-policyhttps://www.polarismarketresearch.com/privacy-policy
The global Subcutaneous Drug Delivery Devices Market in terms of revenue was estimated to be worth $30.43 bn in 2023 & is poised to reach $53.50 bn by 2032, growing at a CAGR of 6.5% from 2024 to 2032.
https://www.techsciresearch.com/privacy-policy.aspxhttps://www.techsciresearch.com/privacy-policy.aspx
Global Drug Delivery Devices Market was valued at USD 240.62 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.80% through 2029.
Pages | 185 |
Market Size | 2023: USD 240.62 Billion |
Forecast Market Size | 2029: USD 375.98 Billion |
CAGR | 2024-2029: 7.80% |
Fastest Growing Segment | Injectable |
Largest Market | North America |
Key Players | 1. Pfizer Inc. 2. Novartis AG 3. F Hoffmann-La Roche Ltd 4. Johnson and Johnson 5. Bayer AG 6. Becton, Dickinson and Company 7. Altaris Capital Partners, LLC 8. Holozymes Inc. (Antares Pharma Inc.) 9. GlaxoSmithKline PLC 10. Teva Pharmaceutical Industries Ltd |
https://www.transparencymarketresearch.com/privacy-policy.htmlhttps://www.transparencymarketresearch.com/privacy-policy.html
On-body Drug Delivery Devices Market Overview
Attribute | Detail |
---|---|
Market Drivers |
|
Regional Analysis of On-body Drug Delivery Devices Market
Attribute | Detail |
---|---|
Leading Region | North America |
On-body Drug Delivery Devices Market Snapshot
Attribute | Detail |
---|---|
Market Size in 2023 | US$ 390.7 Mn |
Market Forecast (Value) in 2034 | US$ 796.1 Mn |
Growth Rate (CAGR) | 6.8% |
Forecast Period | 2024-2034 |
Historical Data Available for | 2020-2022 |
Quantitative Units | US$ Bn for Value |
Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
Competition Landscape |
|
Format | Electronic (PDF) + Excel |
Market Segmentation |
|
Regions Covered |
|
Countries Covered |
|
Companies Profiled |
|
Customization Scope | Available Upon Request |
Pricing | Available Upon Request |
Drug Delivery Devices Market Size 2024-2028
The drug delivery devices market size is forecast to increase by USD 85.1 billion at a CAGR of 6.2% between 2023 and 2028.
The market is experiencing significant growth due to the increasing prevalence of chronic conditions and the rising adoption of self-administering systems. Self-injectable devices, including auto-injectors and jet-injectors, are gaining popularity for their convenience and effectiveness in delivering drugs directly to the target site. However, bioavailability hurdles remain a challenge in oral delivery systems, leading to the increasing use of injectable routes. Pharmaceutical companies are investing heavily in research and development to address these challenges and create more efficient drug delivery systems.In healthcare, Retail pharmacies and hospital pharmacies are key distribution channels for these devices, ensuring easy access for patients. Stringent government regulations ensure the safety and efficacy of these devices, making them a reliable option for patients. The market is expected to continue growing as technology advances and new applications for drug delivery systems emerge.
What will be the Size of the Market During the Forecast Period?
Request Free Sample
The market represents a significant segment within the pharmaceutical industry, offering innovative solutions for the effective and efficient administration of active pharmaceutical ingredients (APIs) in various therapeutic areas. These devices cater to both chronic diseases and non-chronic diseases, and their usage extends to home-care environments, retail pharmacies, hospital pharmacies, and online pharmacies. Advanced technology plays a crucial role in the development of drug delivery devices. Next-generation technologies, such as self-administering systems, auto-injectors, pen injectors, jet-injectors, prefilled syringes, and smart sensors, have gained popularity due to their patient-friendly designs and improved accuracy. In the context of chronic diseases, drug delivery devices have proven to be essential for targeted medication delivery.
Biologics drugs, which often require specific delivery methods, have particularly benefited from these advancements. The pharmaceutical industry's focus on diagnosis and treatment has led to the integration of drug delivery devices in various vaccination drives and therapeutic areas. Oral drug delivery and injectable drug delivery systems have shown remarkable progress, offering enhanced patient compliance and convenience. Homecare solutions have emerged as a key area of growth within the market. These devices enable patients to administer medications in the comfort of their homes, reducing the need for frequent hospital visits and improving overall patient care.
How is this market segmented and which is the largest segment?
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Route Of Administration
Oral
Injectable
Pulmonary
Others
Geography
North America
Canada
US
Europe
Germany
UK
Asia
Rest of World (ROW)
By Route Of Administration Insights
The oral segment is estimated to witness significant growth during the forecast period.
The market for Drug Delivery Devices encompasses various types of devices used for administering drugs, including Injection Devices, Oral Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, and Nasal Drug Delivery. Among these, the segment for Oral Drug Delivery is significant due to its ease of use, non-invasive nature, and cost-effectiveness. This segment includes drugs in the form of capsules, tablets, syrups, solutions, and suspensions
Furthermore, orally administered drugs can be targeted to specific areas within the gastrointestinal tract to treat various conditions, including cancer, inflammation, infections, and bowel diseases. Advancements in pharmaceutical technologies and oral drug delivery systems, such as lipid-based carriers, nanocarriers, and micelles, are enhancing oral drug absorption, thereby improving therapeutic effectiveness. Hence, such factors are fuelling the growth of this segment during the forecast period.
Get a glance at the market report of share of various segments Request Free Sample
The oral segment was valued at USD 85.50 billion in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 52% to the growth of the global market during the forecast period.
Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sampl
https://www.rootsanalysis.com/privacy.htmlhttps://www.rootsanalysis.com/privacy.html
Global connected drug delivery devices market size is expected to grow from USD 4.4 bn in 2024 to USD 4.8 bn in 2025 and USD 12.7 bn by 2035, at CAGR of 10.1%
https://www.rootsanalysis.com/privacy.htmlhttps://www.rootsanalysis.com/privacy.html
The targeted drug delivery device market was valued at $427 million in 2026 to $2,153 million by 2035, representing a CAGR of 19.7%.
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
Italy Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal Patches, Oral Mucosal and More), Application (Cancer, Cardiovascular, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
https://bisresearch.com/privacy-policy-cookie-restriction-modehttps://bisresearch.com/privacy-policy-cookie-restriction-mode
Non-Invasive drug delivery devices market is segmented into products types, application. Market to grow at a CAGR of 23.13% during forecast period 2019 to 2025. Non-Invasive drug delivery devices market report by BIS Research provides deep market insight that will help your business to grow.
https://www.researchnester.comhttps://www.researchnester.com
The global drug delivery devices market size was worth more than USD 301.94 billion in 2024 and is poised to witness a CAGR of over 5.8%, crossing USD 628.4 billion revenue by 2037. Injectable segment is expected to achieve 39% share by 2037, due to advances in injectable drug delivery techniques and rising global vaccination efforts.
https://www.verifiedmarketresearch.com/privacy-policy/https://www.verifiedmarketresearch.com/privacy-policy/
Drug Delivery Devices Market size was valued at USD 2.13 Billion in 2022 and is projected to reach USD 7.96 Billion by 2030 growing at a CAGR of 16.27% From 2024-2030.The global Drug Delivery Devices Market is expanding primarily due to the increasing prevalence of the chronic disease across the globe. Due to lifestyle choices and lack of physical exercise, the cases of diabetes, cardiovascular diseases, and cancer have exponentially increased in the past decade. This has promoted the key players to launch innovative medications and invest heavily in R&D activities. Such developments have greatly propelled the market for drug-delivery devices. The leading market players are introducing innovative products that offer better drug efficacy while reducing side effects, which is expected to open many attractive opportunities during the forecast period.
https://www.zionmarketresearch.com/privacy-policyhttps://www.zionmarketresearch.com/privacy-policy
Global transmucosal drug delivery devices market was valued at USD 46.63 Bn in 2024 and is predicted to USD 86.64 Bn by 2034, with a CAGR of 6.39%.
https://www.imarcgroup.com/privacy-policyhttps://www.imarcgroup.com/privacy-policy
The global implantable drug delivery devices market size reached USD 15.24 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.58 Billion by 2033, exhibiting a growth rate (CAGR) of 6.47% during 2025-2033. The increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, the growing geriatric population susceptible to chronic disorders, and rapid technological advancements in implantable devices are some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
| USD 15.24 Billion |
Market Forecast in 2033
| USD 27.58 Billion |
Market Growth Rate 2025-2033 | 6.47% |
IMARC Group provides an analysis of the key trends in each segment of the global implantable drug delivery devices market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on product type, technology, application, and end user.
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
United Kingdom Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Application (Diabetes, Respiratory Diseases, Oncology, and More), and End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
https://www.rootsanalysis.com/privacy.htmlhttps://www.rootsanalysis.com/privacy.html
The diabetes drug delivery devices market is expected to grow at CAGR of 9% during the forecast period.
https://www.techsciresearch.com/privacy-policy.aspxhttps://www.techsciresearch.com/privacy-policy.aspx
The Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.15%.
Pages | 180 |
Market Size | 2024: USD 6.45 Billion |
Forecast Market Size | 2030: USD 15.15 Billion |
CAGR | 2025-2030: 15.25% |
Fastest Growing Segment | Parenteral |
Largest Market | North America |
Key Players | 1. Teva Pharmaceutical Industries Ltd. 2. Novo Nordisk A/S 3. Phillips Medisize 4. Medtronic Plc. 5. Adherium Limited 6. Tandem Diabetes Care, Inc. 7. Biocorp Life Sciences Pvt. Ltd 8. Resmed Corp 9. Ypsomed AG 10. AptarGroup, Inc |
https://www.researchnester.comhttps://www.researchnester.com
The global drug delivery systems market size exceeded USD 47.47 billion in 2024 and is set to expand at a CAGR of over 8.3%, surpassing USD 133.84 billion revenue by 2037. Diabetes segment is poised to capture 33% share by 2037, attributed to rising number of diabetes patients globally and the growing use of insulin injections among diabetes patients.
https://market.us/privacy-policy/https://market.us/privacy-policy/
Global Drug Delivery Devices Market size is expected to be worth around US$ 862.16 Billion by 2034 from US$ 410.61 Billion in 2024.